Skip to main content
MLTX
NASDAQ Life Sciences

CEO Files Intent to Sell $2.79 Million in Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$19.28
Mkt Cap
$1.383B
52W Low
$5.95
52W High
$62.75
52W Position info
224% above low
Off High info
69% below high
Rel. Volume
Market data snapshot near publication time

MLTX has more than doubled off its 52-week low of $5.95.

Summary

MoonLake Immunotherapeutics' CEO, Jorge Pedro Santos Radeck D Silva, has filed a Form 144 indicating intent to sell 150,000 shares, valued at approximately $2.79 million.


Key Events · Ownership and Investor Activity · MLTX

  • CEO Files Intent to Sell Shares

    Jorge Pedro Santos Radeck D Silva, the CEO of MoonLake Immunotherapeutics, has filed a Form 144 indicating his intent to sell 150,000 Class A shares.

  • Proposed Sale Valued at $2.79 Million

    The shares intended for sale are valued at approximately $2.79 million, representing a significant transaction for an executive.

  • Follows Recent Institutional Selling

    This CEO filing comes shortly after BVF Partners, a significant institutional investor and affiliate of a director, reported substantial share sales earlier in April, indicating a broader pattern of insider and institutional distribution.


Analysis · MLTX · Life Sciences

The filing of a Form 144 by CEO Jorge Pedro Santos Radeck D Silva, indicating intent to sell a substantial amount of shares, is a negative signal. This executive selling follows recent significant share dispositions by a major institutional investor, BVF Partners, earlier this month. While the filing only indicates intent, it suggests a potential lack of conviction from a key insider, which could weigh on investor sentiment.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLTX was trading at $19.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.95 to $62.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLTX - Latest Insights

MLTX
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $11.03 info
Change: -$0.570 (-5%) info
Market Cap: $938.727M info
MLTX
Nov 04, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.62
Real-time Price: $11.03 info
Change: -$0.590 (-5%) info
Market Cap: $938.727M info
MLTX
Nov 04, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $11.03 info
Change: -$0.580 (-5%) info
Market Cap: $938.727M info
MLTX
Sep 30, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.81
Real-time Price: $11.03 info
Change: -$0.7807 (-7%) info
Market Cap: $938.727M info
MLTX
Aug 10, 2026, 1:21 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $17.11
Real-time Price: $11.03 info
Change: -$6.08 (-36%) info
Market Cap: $938.727M info